Our study indicates that TEVs produced following IL-1β signaling activation, as well as those from both sensitive and resistant EGFR TKI-treated cells, contribute not only to tumor progression, through enhanced cell migration and EMT modulation, but also to the alterations in immune cell populations, potentially facilitating immune evasion. The gene discussed is IL1B; the disease is neoplasm.